Alirocumab: all 78 studies that test it
Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid PlaqueNot yet recruitingNCT07586540Phase 3
- Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary PreventionRecruitingNCT07581808Phase 4
- TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingNCT06385262Phase 2
- The Effect of Early Administration of PCSK9 Inhibitor to Acute Ischemic Stroke Patients Associated With Atherosclerosis on the Stroke Prognosis and Lipid ProfileNot yet recruitingNCT06083961Phase 4
- Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)Not yet recruitingNCT06080256Phase 3
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNCT05587621Not applicable
- Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium InfarctionRecruitingNCT05292404Phase 4
- Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy DrinkersRecruitingNCT04781322Phase 1
- Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant RecipientsRecruitingNCT04193306Phase 4
- Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 InhibitorsCompletedNCT04189484Phase 1Results posted
- Long Term Safety Study of PRALUENTTerminatedNCT03694197Phase 4Results posted
- Cardiac Allograft Vasculopathy Inhibition With AlirocumabCompletedNCT03537742Phase 2Results posted
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompletedNCT03510884Phase 3Results posted
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT03510715Phase 3Results posted
- Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT03156621Phase 3Results posted
- Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With HypercholesterolemiaCompletedNCT02984982Phase 4Results posted
- Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to PlaceboCompletedNCT02957682Phase 4Results posted
- Alirocumab in Patients With Acute Myocardial InfarctionCompletedNCT02938949Phase 4Results posted
- An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompletedNCT02890992Phase 2Results posted
- Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With HypercholesterolemiaCompletedNCT02715726Phase 3Results posted
- Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)CompletedNCT02642159Phase 4Results posted
- Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)CompletedNCT02585778Phase 3Results posted
- Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of StatinCompletedNCT02584504Phase 3Results posted
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)CompletedNCT02476006Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis TherapyCompletedNCT02326220Phase 3Results posted
- Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)CompletedNCT02107898Phase 3Results posted
- Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)CompletedNCT02023879Phase 3Results posted
- Open Label Study of Long Term Safety Evaluation of AlirocumabCompletedNCT01954394Phase 3Results posted
- Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)CompletedNCT01926782Phase 3Results posted
- Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in JapanCompletedNCT01812707Phase 2Results posted
- Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)CompletedNCT01730053Phase 3Results posted
- Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)CompletedNCT01730040Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)CompletedNCT01709513Phase 3Results posted
- Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)CompletedNCT01709500Phase 3Results posted
- ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabCompletedNCT01663402Phase 3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With HypercholesterolemiaCompletedNCT01644474Phase 3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)CompletedNCT01644188Phase 3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)CompletedNCT01644175Phase 3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying TherapyCompletedNCT01623115Phase 3Results posted
- Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)CompletedNCT01617655Phase 3Results posted
- A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneCompletedNCT01604824Phase 2Results posted
- Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT01576484Phase 2Results posted
- Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)CompletedNCT01507831Phase 3Results posted
- Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary HypercholesterolemiaCompletedNCT01288469Phase 2Results posted
- Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin TherapyCompletedNCT01288443Phase 2Results posted
- Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH HypercholesterolemiaCompletedNCT01266876Phase 2Results posted
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaActive, not recruitingNCT07477704Phase 2
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell LungActive, not recruitingNCT05553834Phase 2
- Alirocumab in Patients with SepsisCompletedNCT05469347Phase 1
- Alirocumab and Plaque Burden In Familial HypercholesterolaemiaCompletedNCT05465278Phase 4
- Trial of PCSK9 Inhibition in Patients with Acute Stroke and Symptomatic Intracranial AtherosclerosisActive, not recruitingNCT05001984Phase 2
- Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and TreatmentStatus unknownNCT04613167Not applicable
- Early Alirocumab to Reduce LDL-C in Myocardial InfarctionWithdrawnNCT03750760Phase 4
- Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCICompletedNCT03718286Phase 2
- Treatment of Severe Infection With Antihyperlipidemia DrugStatus unknownNCT03634293Phase 2/3
- The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence TomographyStatus unknownNCT03552432Phase 4
- The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot TrialTerminatedNCT03542110Phase 4
- Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular UltrasoundStatus unknownNCT03529253Phase 4
- Alirocumab in Patients on a Stable Dialysis RegimenStatus unknownNCT03480568Phase 3
- Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV DiseaseStatus unknownNCT03355027Not applicable
- Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 DiabetesCompletedNCT03344692Phase 3
- Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)CompletedNCT03207945Phase 3
- Vascular Effects of Alirocumab in Acute MI-PatientsCompletedNCT03067844Phase 3
- Alirocumab and Reverse Cholesterol TransportCompletedNCT03014830Phase 1
- Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic SyndromeTerminatedNCT03004001Phase 2
- Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With AlirocumabStatus unknownNCT02992301Phase 4
- A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese SubjectsCompletedNCT02979015Phase 1
- A Trial of Alirocumab and Plaque Regression in Peripheral Arterial DiseaseCompletedNCT02959047Phase 4
- Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-CholesterolCompletedNCT01959971Phase 1
- Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy SubjectsCompletedNCT01785329Phase 1
- Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy SubjectsCompletedNCT01670734Phase 1
- Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy VolunteersCompletedNCT01448317Phase 1
- Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)CompletedNCT01448304Phase 1
- Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)CompletedNCT01448239Phase 1
- Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy SubjectsCompletedNCT01443650Phase 1
- Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant AtorvastatinCompletedNCT01161082Phase 1
- Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy VolunteersCompletedNCT01074372Phase 1
- Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy VolunteersCompletedNCT01026597Phase 1